Clinical Trials Logo

Steroid Refractory GVHD clinical trials

View clinical trials related to Steroid Refractory GVHD.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05017688 Recruiting - Clinical trials for Steroid Refractory GVHD

Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013

ORION
Start date: October 6, 2021
Phase: N/A
Study type: Interventional

The objective of the ORION study is to explore the changes of gut microbiota composition following MaaT013 administration and its impact on the immune system in GVHD patients.

NCT ID: NCT04769895 Recruiting - Clinical trials for Steroid Refractory GVHD

MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

ARES
Start date: March 25, 2022
Phase: Phase 3
Study type: Interventional

MaaT013 showed interesting results in steroids and ruxolitinib-resistant aGVHD patients with gut involvement (55% ORR at D28) and 47% and 39% OS at 6 and 12 months respectively (Malard 2020), therefore warrant being tested as salvage therapy in steroid and JAK inhibitors-resistant GI-aGvHD patients. Given the absence of an approved 3rd line strategy or 2nd line strategy in ruxolitinib intolerant patients and the extremely poor prognosis of these patients, who are mostly left with no viable therapeutic option, a single-arm open-label design was proposed.